ARTICLE | Company News

Kosan, Bristol-Myers deal

June 2, 2008 7:00 AM UTC

Simultaneously, Bristol-Myers received an exclusive, worldwide license to Kosan’s epothilone compounds as a backup deal. If the acquisition does not go through, Kosan would receive $25 million up front and be eligible for $400 million in milestones, plus royalties. Kosan also has PF-04548043 (KOS-2187), a second-generation erythromycin-derived motilin agonist in Phase I testing to treat gastroesophageal reflux disease (GERD) that is exclusively licensed to Pfizer Inc. (NYSE:PFE, New York, N.Y.). ...